The recent availability of brentuximab vedotin [14,15] and programmed cell death-1 (PD-1) checkpoint inhibitors [16] has significantly expanded the therapeutic armamentarium, thereby providing curative options for a proportion of relapsed/refractory cHL. The gene discussed is PDCD1; the disease is classic Hodgkin lymphoma.